Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers

Pharmaceutical Research

Volumn 15, Issue 3, 1998, Pages 423-428

  Alsenz, Jochem ^a,b   Steffen, Hans ^a   Alex, Rainer ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Caco 2 cells; Efflux system; HIV protease inhibitors; Ritonavir; Saquinavir

Indexed keywords

GLYCOPROTEIN P; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CELL CULTURE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG TRANSPORT; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; PERMEABILITY; PRIORITY JOURNAL; SCINTIGRAPHY; TECHNIQUE; TEMPERATURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CYCLOSPORINE; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; P-GLYCOPROTEIN; RITONAVIR; SAQUINAVIR; VERAPAMIL; VINBLASTINE;

EID: 0031896882     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011924314899     Document Type: Article

References (30)

1. S. Noble and D. Faulds. Saquinavir; A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93-112 (1996).
2. J. M. Schapiro, M. A. Winters, F. Stewart, B. Efron, J. Norris, M. J. Kozal, and T. C. Merigan. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. 124:1039-1050 (1996).
3. D. J. Kempf, K. C. Marsh, J. F. Denissen, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488 (1995).
4. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 9 USA, Sep 17-20, (1995).
5. A. Hsu, G. R. Grannermann, E. Sun, C P. Chen, T. El-Shourbagy, C. Locke, P. Barold, L. Carothers, G. Cao, J. Quian, D. Pizzuti, F. Stewart, and J. Leonard. Assessment of single- and multipledose interactions between ritonavir and saquinavir. XI. International Conference on AIDS, Vancouver, Canada, July. 7-12, (1996).
6. U. A. Germann. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J. Cancer 32A:927-944 (1996).
7. I. K. Pajeva, M. Wiese, H.-P. Cordes, and J. K. Seydel. Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. J. Cancer. Res. Clin. Oncol. 122:27-40 (1996).
8. G. Ecker and P. Chiba. Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein - an overview. Wien. Klin. Wochenschr. 107/22:681-686 (1997).
9. J. Hunter, B. H. Hirst, and N. L. Simmons. Drug absorption limited by p-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10:743-749 (1993).
10. G. Fricker, J. Drewe, J. Huwyler, H. Gutmann, and C. Beglinger. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro - in vivo correlation. Br. J. Pharmacol. 118:1841-1847 (1996).
11. J. Hunter, M. A. Jepson, T. Tsuruo, N. L. Simmons, and B. H. Hirst. Functional expression of p-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 268:14991-14997 (1993).
12. P. Wils, V. Phung Ba, A. Warnery, D. Lechardeur, S. Raeissi, I. J. Hidalgo, and D. Scherman. Polarized transport of docetaxel and vinblastine mediated by p-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 48:1528-1530 (1994).
13. K. Hosoya, K. Kim, and V. H. Lee. Age-dependent expression of p-glycoprotein gp170 in Caco-2 cell monolayers. Pharm. Res. 13:885-890 (1996).
14. J. Ficorilli, B. Anderson, F. Thompson, and J. D. Fondacaro. Effects of co-solvents on mannitol permeability in Caco-2 monolayers. Pharm. Res. 13 Suppl S-411 (1996).
15. P. Artursson. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79:476-482 (1990).
16. P. Artursson, J. Karlsson, G. Ocklind, N. and Schipper. Shaw, A. "Cell culture models of epithelia". A practical approach. IRL Press, 1996, pp. 111-133.
17. A. Tsuji, I. Tamai, A. Sakata, Y. Tenda, and T. Terasaki. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P glycoprotein. Biochem. Pharmacol. 46:1096-1099 (1993).
18. P. F. Augustijns, T. B. Bradshaw, L.-S. L. Gan, R. W. Hendren, and D. R. Thakker. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Comm. 197:360-365 (1993).
19. G. Krishna, W. H. Barr, and C. O. Watlington. The evaluation of cytochrome P4503A4 activity in Caco-2 monolayers. Pharm. Res. 13 Suppl: S-n439(1996).
20. L. S. Gan, M. A. Moseley, B. Khosla, P. F. Augustijns, T. P. Bradshaw, R. W. Hendren, and D. R. Thakker. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug. Metab. Dispos. 24:344-349 (1996).
21. Hoffmann-La Roche (Welwyn). A four-week oral combination toxicity and toxicokinetic study of Ro31-89591/A 12 (Saquinavir®) and A-84538 (Ritonavir) in dogs (1996) (Data on file).
22. V. J. Wacher, C. -Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogenesis 13:129-134 (1995).
23. L. Z. Benet, C. -Y. Wu, M. F. Henert, and V. J. Wacher. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J. Control. Release 39:139-143 (1996).
24. C. T. Ueda, M. Lamaire, G. Gsell, P. Misslin, and K. Nussbaumer. Apparent dose-dependent oral absorption of cyclosporin A in rats. Biopharm. Drug Dispos. 5:141-151 (1984).
25. G. Moyle and B. Gazzard. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 51:701-712 (1996).
26. G. N. Kumar, A. D. Rodrigues, A. M. Buko, and J. F. Denissen. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir(ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423-431 (1996).
27. D. Leveque and F. Jehl. P-glycoprotein and pharmacokinetics. Anticancer Res. 15:331-336 (1995).
28. A. Tsuji, I. Tamai, A. Sakata, Y. Tenda, and T. Terasaki. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Blochem. Pharmacol. 46:1096-1099 (1993).
29. th Conference on Retroviruses and Opportunistic Infections (1997).
30. Nelfinavir: general information, study results (CD4 and viral load), dosing schedule, eating instructions, drug interactions, combination with other protease inhibitors and NNRTIs, side effects, resistance, cross resistance. Information provided by National AIDS Treatment Advocacy Project (NATAP) (1997) (http:// www.aidsnyc. org/natap/drug/nelfpkg.html).